Pharmacology of histone deacetylase inhibitor

A tétel rövid nézete
dc.contributor.advisorPórszász, Róbert
dc.contributor.advisordeptDebreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet
dc.contributor.authorKim, Hanbin
dc.contributor.departmentDE--Általános Orvostudományi Kar
dc.contributor.opponentHalasi, Barbara
dc.contributor.opponentMegyeri, Attila
dc.contributor.opponentdeptDebreceni Egyetem::Általános Orvostudományi Kar::Igazságügyi Orvostani Intézet
dc.contributor.opponentdeptDebreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet
dc.date.accessioned2023-07-20T09:01:50Z
dc.date.available2023-07-20T09:01:50Z
dc.date.created2023-05-18
dc.description.abstractMy thesis is about histone deactylase inhibitor which inhibit acetylation in lysine residues of core histones. HDAC inhibitor involved in cell proliferation and death, altering their function. HDACIs have been studied for their potential therapeutic use in various diseases, including cancer, neurodegerative disease, and inflammatory disorder. Their is several drugs for example vorinostat, valproic acid, trichostatin A etc. HDACI have limitation which is lack of specificity, potential to induce resistance, and limited efficacy in certain tumor types. HDACIs have shown promise in preclinical and clinical studies for the treatment of various diseases, further research is needed to fully understand their pharmacological properties and potential therapeutic uses.
dc.description.courseáltalános orvos
dc.description.courselangangol
dc.description.degreeegységes, osztatlan
dc.format.extent28
dc.identifier.urihttps://hdl.handle.net/2437/357725
dc.language.isoen
dc.subjectanticancer
dc.subjecthistone deactylase
dc.subject.dspaceDEENK Témalista::Orvostudomány::Gyógyszerésztudomány
dc.titlePharmacology of histone deacetylase inhibitor
dc.title.translatedPharmacology of histone deacetylase inhibitor
Fájlok
Gyűjtemények
Theses (Faculty of Medicine)